NCT05523739View on ClinicalTrials.gov

Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

September 16, 2022

Primary Completion Date

December 21, 2022

Study Completion Date

March 29, 2023

Conditions
SARS-CoV-2 Infection
Interventions
DRUG

STI-1558

An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).

Trial Locations (1)

Unknown

The Third People's Hospital Of Shenzhen, Shenzhen

All Listed Sponsors
lead

Zhejiang ACEA Pharmaceutical Co. Ltd.

INDUSTRY